Tricida, Inc. (TCDA) Research

Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.

Market snapshot

Symbol
TCDA
Price
$0.11
Day change
0.00%
Market cap
$6.0M
P/E ratio
-0.03x
52-week range
0.0411-13.85
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$16.00

Peer companies

  • Aptose Biosciences Inc. (APTO)
  • BiondVax Pharmaceuticals Ltd. (BVXV)
  • Entero Therapeutics, Inc. (ENTO)
  • Fresh Tracks Therapeutics, Inc. (FRTX)
  • Gamida Cell Ltd. (GMDA)
  • ModivCare Inc. (MODV)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Tectonic Therapeutic, Inc. (TECX)

Recent insider activity

  • ORBIMED ADVISORS LLC — S-Sale (1034421 shares) on 2022-11-22
  • ORBIMED ADVISORS LLC — S-Sale (5617300 shares) on 2022-11-23
  • ORBIMED ADVISORS LLC — S-Sale (3629226 shares) on 2022-11-25
  • Bonita David P — S-Sale (1034421 shares) on 2022-11-22
  • Bonita David P — S-Sale (5617300 shares) on 2022-11-23

Open Tricida, Inc. (TCDA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.